Asbestosis

EAST WENATCHEE RETIRED TEACHER WINS $10 MILLION JUDGEMENT IN ASBESTOS CASE

Retrieved on: 
Monday, December 13, 2021
Judgement, World War II, Asbestosis, Mineral, Vigor Shipyards, Lung, Diagnosis, Cancer, Disease, Mesothelioma, Lung cancer, Asbestos, Pleural cavity, Aluminium, Retirement, Family, Bergman, Scar, King County Superior Court, Population, Tobacco, Degenerative disease, Buzzi Unicem, Oil, Shipbuilding, Plaster

SEATTLE, Dec. 13, 2021 /PRNewswire/ -- A unanimous King County jury has awarded $10 million to George Kraemer, 79 of East Wenatchee who is suffering from mesothelioma, a cancer caused by exposure to asbestos.

Key Points: 
  • SEATTLE, Dec. 13, 2021 /PRNewswire/ -- A unanimous King County jury has awarded $10 million to George Kraemer, 79 of East Wenatchee who is suffering from mesothelioma, a cancer caused by exposure to asbestos.
  • Kramer's father Charles Kraemer worked as an insulator at the shipyard and brought asbestos fibers home on his contaminated work clothes, exposing his entire family to toxic dust.
  • "We are grateful the court found in favor of our case," said Kraemer.
  • A middle school science teacher, coach, and administrator; Kraemer's career spanned more than 30 years including the Shoreline, Lake Washington and Eastmont school districts.

UKLS Trial Meta-Analysis Confirms that Low Dose CT Screening for Lung Cancer Reduces Mortality

Retrieved on: 
Monday, September 13, 2021
WCLC, Association, COPD, LLP, Lung cancer, University, Professor, Conference, Bronchitis, Journal of Thoracic Oncology, Asbestosis, Cancer, Tuberculosis, Tobacco, Pipe smoking, Clinical trial, Mortality, Respiratory disease, Physician, Pneumonia, International Association, Randomized controlled trial, Meta-analysis, University of Liverpool, Death, Wald, History, Diagnosis, Lung, Research, Awareness, Smoking, Medical imaging, Pharmaceutical industry

DENVER, Sept. 13, 2021 /PRNewswire/ --Low-dose CT lung cancer (LDCT) screening is associated with a 16 percent relative reduction in lung cancer mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team today at the IASLC 2021 World Conference on Lung Cancer.

Key Points: 
  • DENVER, Sept. 13, 2021 /PRNewswire/ --Low-dose CT lung cancer (LDCT) screening is associated with a 16 percent relative reduction in lung cancer mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team today at the IASLC 2021 World Conference on Lung Cancer.
  • Previous studies, such as the National Lung Cancer Screening Trial and The NELSON LDCT screening trial, provided evidence of a statistically significant reduction (20%, 24% respectively) in lung cancer mortality.
  • Results from these nine randomized controlled trials were included in the meta-analysis indicated a significant reduction in lung cancer mortality.
  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.

UKLS Trial Meta-Analysis Confirms that Low Dose CT Screening for Lung Cancer Reduces Mortality

Retrieved on: 
Monday, September 13, 2021
WCLC, Association, COPD, LLP, Lung cancer, University, Professor, Conference, Bronchitis, Journal of Thoracic Oncology, Asbestosis, Cancer, Tuberculosis, Tobacco, Pipe smoking, Clinical trial, Mortality, Respiratory disease, Physician, Pneumonia, International Association, Randomized controlled trial, Meta-analysis, University of Liverpool, Death, Wald, History, Diagnosis, Lung, Research, Awareness, Smoking, Medical imaging, Pharmaceutical industry

DENVER, Sept. 13, 2021 /PRNewswire/ --Low-dose CT lung cancer (LDCT) screening is associated with a 16 percent relative reduction in lung cancer mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team today at the IASLC 2021 World Conference on Lung Cancer.

Key Points: 
  • DENVER, Sept. 13, 2021 /PRNewswire/ --Low-dose CT lung cancer (LDCT) screening is associated with a 16 percent relative reduction in lung cancer mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team today at the IASLC 2021 World Conference on Lung Cancer.
  • Previous studies, such as the National Lung Cancer Screening Trial and The NELSON LDCT screening trial, provided evidence of a statistically significant reduction (20%, 24% respectively) in lung cancer mortality.
  • Results from these nine randomized controlled trials were included in the meta-analysis indicated a significant reduction in lung cancer mortality.
  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.

Global Respiratory Partnering Deal Trends, Players and Financials Directory 2010-2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Health, Other Health, Lung disorders, Respiratory diseases, Anatomy, Organ systems, Asbestosis, Wheeze, Pulmonary fibrosis, Lung, Respiratory disease, Occupational lung disease, Respiratory system, Respiratory tract

b'The "Global Respiratory Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Respiratory Partnering 2010 to 2021 report provides comprehensive access to available deals and contract documents for over 850 respiratory deals.\nMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor\'s product or technology.

Key Points: 
  • b'The "Global Respiratory Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Respiratory Partnering 2010 to 2021 report provides comprehensive access to available deals and contract documents for over 850 respiratory deals.\nMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor\'s product or technology.
  • More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.\nThe report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.\nThe report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.\nIn addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2010.
  • The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type.
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\nThe report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestation, Snoring, Wheeze, plus other respiratory indications.\nGlobal Respiratory Partnering 2010 to 2021 includes:\nAvailable deals and contracts are listed by:\n'

Biotechs Search for Innovative Methods to Combat Common Diseases

Retrieved on: 
Monday, March 4, 2019
Lung, Organ systems, Respiratory system, Interstitial lung disease, Respiratory tract, Pulmonary alveolus, Respiratory disease, Occupational diseases, RTT, Acute interstitial pneumonitis, Asbestosis

Other common medical conditions that are found around the world include lung diseases.

Key Points: 
  • Other common medical conditions that are found around the world include lung diseases.
  • Lung diseases are primarily caused by family genetics, but can also result from allergies, being overweight, smoking, and exposure to pollutants.
  • There are various classifications of lung diseases, such as diseases that affect the airway, air sacs, and blood vessels, but the concern over interstitial lung diseases has recently become more prevalent.
  • Interstitial lung diseases (ILD) affect the interstitium, which is a microscopically thin, delicate lining between the lungs' air sacs.

Biotechs Search for Innovative Methods to Combat Common Diseases

Retrieved on: 
Monday, March 4, 2019
Lung, Organ systems, Respiratory system, Interstitial lung disease, Respiratory tract, Pulmonary alveolus, Respiratory disease, Occupational diseases, RTT, Acute interstitial pneumonitis, Asbestosis

Other common medical conditions that are found around the world include lung diseases.

Key Points: 
  • Other common medical conditions that are found around the world include lung diseases.
  • Lung diseases are primarily caused by family genetics, but can also result from allergies, being overweight, smoking, and exposure to pollutants.
  • There are various classifications of lung diseases, such as diseases that affect the airway, air sacs, and blood vessels, but the concern over interstitial lung diseases has recently become more prevalent.
  • Interstitial lung diseases (ILD) affect the interstitium, which is a microscopically thin, delicate lining between the lungs' air sacs.